The KRAS-G12D mutation induces metabolic vulnerability in B-cell acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2022 at "iScience"
DOI: 10.1016/j.isci.2022.103881
Abstract: Summary Mutations in RAS pathway genes are highly prevalent in acute lymphoblastic leukemia (ALL). However, the effects of RAS mutations on ALL cell growth have not been experimentally characterized, and effective RAS-targeting therapies are being… read more here.
Keywords: kras g12d; g12d mutation; acute lymphoblastic; lymphoblastic leukemia ... See more keywords
Fusobacterium nucleatum promotes tumor progression in KRAS p.G12D-mutant colorectal cancer by binding to DHX15
Sign Up to like & getrecommendations! Published in 2024 at "Nature Communications"
DOI: 10.1038/s41467-024-45572-w
Abstract: Fusobacterium nucleatum (F. nucleatum) promotes intestinal tumor growth and its relative abundance varies greatly among patients with CRC, suggesting the presence of unknown, individual-specific effectors in F. nucleatum-dependent carcinogenesis. Here, we identify that F. nucleatum… read more here.
Keywords: crc; g12d mutant; nucleatum promotes; fusobacterium nucleatum ... See more keywords
Trametinib as a promising therapeutic option in alleviating vascular defects in an endothelial KRAS-induced mouse model.
Sign Up to like & getrecommendations! Published in 2022 at "Human molecular genetics"
DOI: 10.1093/hmg/ddac169
Abstract: Somatic activating Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations have been reported in patients with arteriovenous malformations. By producing LSL-Kras (G12D); Cdh5 (PAC)-CreERT2 [iEC-Kras (G12D*)] mice, we hoped to activate KRAS within vascular endothelial… read more here.
Keywords: kras induced; kras g12d; trametinib; iec kras ... See more keywords
The Oxidative Drug Combination for Suppressing KRAS G12D Inducible Tumour Growth
Sign Up to like & getrecommendations! Published in 2022 at "BioMed Research International"
DOI: 10.1155/2022/9426623
Abstract: Background Kirsten rat sarcoma (KRAS) protein is an essential contributor to the development of pancreatic ductal adenocarcinoma (PDAC). KRAS G12D and G12V mutant tumours are significant challenges in cancer therapy due to high resistance to… read more here.
Keywords: kras g12d; ato; combination; drug combination ... See more keywords
Abstract C058: Vitamin C preferentially induces growth inhibition and cell death in KRAS G12D-mutant pancreatic cancer cells
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-c058
Abstract: Vitamin C (L-Ascorbic acid, VC), an anti-oxidant has been studied as the possible potent chemotherapeutic drug in various cancers including colorectal cancer, breast cancer, ovarian cancer, prostate cancer and lung cancer. In particular, it is… read more here.
Keywords: growth; kras g12d; cancer cells; cancer ... See more keywords
Abstract A060: Characterization of PSTA-5204, an oral KRAS G12D (ON) inhibitor with potent in vitro and in vivo efficacy
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-a060
Abstract: The KRAS G12D mutation is one of the most prevalent oncogenic RAS alterations, particularly in pancreatic (∼40%), colorectal (∼15%), and non-small cell lung cancers (∼5%). Therapeutic strategies targeting this mutation include KRAS G12D inhibitors designed… read more here.
Keywords: psta 5204; g12d inhibitor; oral kras; kras g12d ... See more keywords
Abstract A070: Optimal efficacious dose prediction of a novel protein degrader ASP3082 selectively targeting KRAS G12D using quantitative systems pharmacology
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-a070
Abstract: KRAS is a membrane-bound protein and a member of the RAS family of GTPases. It acts as a molecular switch to turn on or off receptor tyrosine kinase signal transduction by binding to GTP or… read more here.
Keywords: cancer; pharmacology; model; efficacious dose ... See more keywords
Abstract A071: Non-clinical study of ASP4396, a novel KRAS G12D degrader, shows remarkable anti-tumor activity in KRAS G12D mutant cancer models
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-a071
Abstract: Mutated KRAS is the well-known oncogene with the highest mutation rates and is known to initiate the oncogenic signaling pathways in many types of cancer with a poor prognosis. Among the variety of point mutations… read more here.
Keywords: cancer; kras g12d; non clinical; g12d degrader ... See more keywords
Abstract A076: VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with superior anti-tumor efficacy relative to ON-only KRAS inhibitors
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-a076
Abstract: KRAS G12D is the most prevalent KRAS mutation in human cancers, present in 37%, 12.5%, and 4.9% of pancreatic, colorectal and lung cancers, respectively. Currently, there are no FDA-approved RAS inhibitors effective for patients with… read more here.
Keywords: rmc 9805; cancer; efficacy; tumor ... See more keywords
Abstract A128: Identification of peptide inhibitors of KRAS G12D and Q61H mutant protein for cancer therapy
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-a128
Abstract: The G12D mutation in the KRAS gene is one of the most common oncogenic mutations and acts as an important oncogenic mechanism in various cancers. In particular, this mutation, which is found in about 40%… read more here.
Keywords: cancer; kras g12d; mutant protein; g12d q61h ... See more keywords
Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5735
Abstract: KRAS is one of the most frequently mutated oncogenes in various cancers. Among KRAS mutations, KRAS G12D is the most frequent driver mutation and is found in approximately 34% of patients with pancreatic ductal adenocarcinoma… read more here.
Keywords: inhibition; antitumor; kras g12d; g12d mutated ... See more keywords